Drug Trial Radar · NCT05134441
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,121
Actual
Start
Nov 18, 2021
Primary completion
Nov 2026
Study completion Sep 2033
Sponsor
- Lead sponsor
- Immunic AGIndustry
- Sponsor type
- Industry
- First posted
- Nov 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
Conditions
- Multiple Sclerosis
Interventions
IMU-838 tabletsDrug
Patients are randomized to IMU-838 or placebo in ratio 1:1
Placebo matching IMU-838 tabletsDrug
Patients are randomized to IMU-838 or placebo in ratio 1:1
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate efficacy of IMU-838 versus placebo regarding time to first relapseTime frame: 72 weeks
Locations
103 sites in 17 countries. Site status is shown where the registry gives one.
Xenoscience, Inc., 21st Century Neurology
Phoenix, Arizona
Regina Berkovich MD, PhD Inc. MS Neurology
West Hollywood, California
Bradenton Research Center
Bradenton, Florida
Collier Neurologic Specialists
Naples, Florida
Neurology Associates of Ormond Beach
Ormond Beach, Florida
Consultants in Neurology, Ltd
Northbrook, Illinois
Klinika Mjekesore Nuova, Neurology Clinic
Tirana, Albania
Hygeia Hospital Tirana
Tirana, Albania
University Hospital Center Mustapha Pacha, Algiers
Algiers, Algeria
University Hospital Center Ibn Sina, Annaba
Annaba, Algeria
University Hospital Center of Oran
Oran, Algeria
MHAT Puls AD
Blagoevgrad, Bulgaria
MHAT "Heart and Brain", EAD
Burgas, Bulgaria
MC Exacta Medica OOD
Pleven, Bulgaria
MHAT Avis Medica
Pleven, Bulgaria
UMHAT Dr.Georgi Stranski EAD
Pleven, Bulgaria
Heart and Brain University Hospital
Pleven, Bulgaria
MC Vita 1
Pleven, Bulgaria
UMHAT "Kaspela"EOOD
Plovdiv, Bulgaria
UMHAT "Pulmed" Ltd
Plovdiv, Bulgaria
UMHAT Sveti Georgi
Plovdiv, Bulgaria
UMHAT "Medica Ruse"
Rousse, Bulgaria
CCB Medical Institute Ministry of Interior
Sofia, Bulgaria
Diagnostic and Consultative Center Neoclinic
Sofia, Bulgaria
UMHAT "Sveti Ivan Rilski" EAD
Sofia, Bulgaria
MHATNP "Sveti Naum", EAD
Sofia, Bulgaria
MHATNPsy Sveti Naum EAD
Sofia, Bulgaria
UMHAT "Alexandrovska" EAD
Sofia, Bulgaria
UMHAT "Alexandrovska"
Sofia, Bulgaria
Military Medical Academy MHAT
Sofia, Bulgaria
MHAT "Sveta Sofia" EOOD
Sofia, Bulgaria
Military Medical Academy
Sofia, Bulgaria
UMHAT"Tsaritsa Yoanna -ISUL
Sofia, Bulgaria
UMHATEM N.Pirogov
Sofia, Bulgaria
UMHAT "Sveta Marina" EAD, First Clinic of Neurological Diseases
Varna, Bulgaria
1st Uni Clinic of Tbilisi LEPL
Tbilisi, Georgia
Eristavi Experimental Center
Tbilisi, Georgia
J.S.C. Curatio Clinic
Tbilisi, Georgia
JSC "Jerarsi"
Tbilisi, Georgia
Khechinashvili University Hospital
Tbilisi, Georgia
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.